New insider activity at AxoGen ( (AXGN) ) has taken place on December 17, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Amy McBride Wendell sold 43,684 shares of AxoGen stock for a total value of $1,280,378. Additionally, Director Kathy Johnson Weiler sold 46,653 shares, amounting to $1,378,195. Meanwhile, CFO Lindsey Marie Hartley sold 14,812 shares for $442,286 in total.
Recent Updates on AXGN stock
Recent developments surrounding AxoGen (AXGN) revolve significantly around the FDA’s approval of its Avance nerve scaffold Biologics License Application (BLA), which transitions the product to a fully licensed biologic with broad applicability for adult and pediatric patients. Analysts attribute multiple price target increases to this milestone, citing strengthened market positioning, enhanced competitive moat, and expanded commercial coverage opportunities. This approval is expected to accelerate market penetration, drive surgeon and societal adoption, and improve sales productivity, setting up favorable growth conditions for 2026. Despite these positives, profitability challenges and valuation concerns persist as noted by expert reports. Overall, this key regulatory achievement is seen as a catalyst for AxoGen’s continued growth and operational improvements.
Spark’s Take on AXGN Stock
According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.
AxoGen’s overall stock score is driven by strong earnings call results and significant corporate events, particularly the FDA approval for Avance Nerve Scaffold. Technical analysis supports a bullish outlook, although valuation concerns due to negative profitability metrics slightly dampen the score.
To see Spark’s full report on AXGN stock, click here.
More about AxoGen
YTD Price Performance: 78.96%
Average Trading Volume: 904,349
Technical Sentiment Signal: Buy
Current Market Cap: $1.35B